How the tilt of a cell-surface receptor prevents cancer
Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?
Jan 31, 2013
0
0
Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?
Jan 31, 2013
0
0
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies ...
Dec 9, 2012
0
0
(Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have ...
Jul 17, 2012
0
0
People with a blood cancer myelofibrosis can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the ...
Feb 29, 2012
0
0
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration
Nov 16, 2011
0
0
(Medical Xpress) -- A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting ...
Jun 23, 2011
0
0
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis ...
Jun 20, 2019
0
3
Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), ...
Aug 19, 2014
0
0
Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at ...
Dec 5, 2013
0
1
British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.
Feb 13, 2013
0
0